Endogenous protease inhibitor uptake within the graft during reperfusion in human liver transplantation

Adult Graft Rejection Male 0303 health sciences CD11 Antigens Neutrophils Enzyme-Linked Immunosorbent Assay Middle Aged Flow Cytometry Prognosis Monocytes Liver Transplantation 3. Good health Intraoperative Period Leukocyte Count 03 medical and health sciences Disease Progression Humans Female Protease Inhibitors L-Selectin Follow-Up Studies Peptide Hydrolases
DOI: 10.1007/s00534-009-0125-3 Publication Date: 2009-05-18T07:38:49Z
ABSTRACT
AbstractBackgroundIn experimental liver transplantation, endogenous protease inhibitors alleviate ischemia–reperfusion (I/R) injury by inhibiting proteolysis and by direct anti‐inflammatory actions. We described the kinetics of endogenous protease inhibitors and explored their anti‐inflammatory potential during reperfusion and their effects on graft function in human liver transplantation.MethodsWe measured circulating levels of protease inhibitors (secretory leukocyte proteinase inhibitor, SLPI; tissue inhibitor of metalloproteinases‐1, TIMP‐1) and proteolytic enzymes (elastase; matrix metalloproteinase‐9, MMP‐9) with ELISA, and neutrophil and monocyte CD11b andl‐selectin expression with flow cytometry during liver transplantation in ten patients. To assess changes within the graft during reperfusion, blood samples from portal and hepatic veins were obtained simultaneously.ResultsCirculating SLPI and TIMP‐1 levels decreased during surgery. During initial reperfusion, the transhepatic SLPI gradient was −27 (−35 to −22) ng/ml,P = 0.005, and TIMP‐1 −510 (−636 to −362) ng/ml,P = 0.005, indicating graft protease inhibitor uptake. Concomitantly, hepatic phagocyte activation and sequestration as well as elastase and MMP‐9 release into the circulation occurred. The transhepatic SLPI gradient correlated with postoperative liver enzymes (ALTR = −0.648,P = 0.043; ALPR = −0.661,P = 0.038; bilirubinR = −0.821,P = 0.004; GGTR = −0.648,P = 0.043).ConclusionsThe results suggest a relative shortage of protease inhibitors within the liver during reperfusion, which may contribute to the development of graft injury.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (31)
CITATIONS (7)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....